Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study

Phase 2 Terminated 2 enrolled Khashayar Esfahani

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm pilot study evaluating the efficacy and safety of tofacitinib in cancer patients with immune-related colitis from immune checkpoint inhibitor (ICI) therapy.

Timeline

Start: 2022-03-22
Primary completion: 2024-01-17
Completion: 2024-01-17

Publications

Background Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tofacitinib	Small molecule	10 mg	Oral

Indications

No indication recorded.